The Lichtsteiner Foundation helps pioneers bring their inventions to life by investing in early stage start-ups in the fields of medical technology, life science, mental health, public health and wellbeing. The foundation focuses on impact investing by providing funding in the form of equity.

The Straumann Group is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Dental Wings, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, biomaterials and digital solutions for use in tooth replacement and restoration or to prevent tooth loss.

Headquartered in Basel, Switzerland, the Group currently employs more than 7700 people worldwide and its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.

With over 30 years’ experience, the Ypsomed Group is a renowned diabetes specialist and principle developer and manufacturer of injection and infusion systems for self-medication. As a leader in innovation and technology, Ypsomed is the preferred partner of pharmaceutical and biotech companies for the supply of injections pens, autoinjectors and infusion systems which administer liquid drugs. Ypsomed promotes its product portfolio under the following umbrella brands: mylife Diabetescare sells directly to patients or via pharmacies and clinics, and YDS Ypsomed Delivery Systems deals business-to-business with pharmaceutical companies.